Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Pulmatrix's annualizedGross Profit for the quarter that ended in Sep. 2024 was $1.46 Mil.
Pulmatrix's average Total Assets over the quarter that ended in Sep. 2024 was $13.65 Mil. Therefore, Pulmatrix's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2024 was 10.73%.
Pulmatrix Gross-Profit-to-Asset % Historical Data
The historical data trend for Pulmatrix's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Pulmatrix's Gross-Profit-to-Asset %
For the Biotechnology subindustry, Pulmatrix's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulmatrix's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pulmatrix's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Pulmatrix's Gross-Profit-to-Asset % falls into.
Pulmatrix Gross-Profit-to-Asset % Calculation
Pulmatrix's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Sep. 2024) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Pulmatrix Gross-Profit-to-Asset % Related Terms
Thank you for viewing the detailed overview of Pulmatrix's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PULM has been successfully added to your 